Gilbert Thill

Title: Gilbert Thill: Innovator in Glycine Transporter Research

Introduction

Gilbert Thill is a notable inventor based in Bois Colombes, France. He has made significant contributions to the field of biotechnology, particularly in the study of glycine transporters. With a total of 2 patents, Thill's work has implications for the treatment and diagnosis of various neurological and psychiatric disorders.

Latest Patents

Thill's latest patents include innovative research on the GlyT1 transporter. The first patent provides polypeptide and polynucleotide sequences for novel splice variants of the sodium and chloride-dependent glycine transporter type 1 (GlyT1). These sequences are crucial for developing treatments for disorders such as schizophrenia. The invention also includes antibodies specifically targeting these novel polypeptides, along with kits that comprise the described polynucleotides, polypeptides, and antibodies. The second patent focuses on methods for identifying and isolating polynucleotides that contain nucleic acid differences within a sample. This method is instrumental in detecting alternative splicing events and genomic DNA differences, utilizing a single-stranded trap involving single-strand binding protein.

Career Highlights

Throughout his career, Gilbert Thill has worked with prominent companies in the biotechnology sector. He has been associated with Gensat S.A. and Serono Genetics Institute S.A., where he has contributed to various research projects and innovations.

Collaborations

Thill has collaborated with notable colleagues, including Philippe Jais and Pascale Grel. Their combined expertise has furthered advancements in the field of glycine transporter research.

Conclusion

Gilbert Thill's contributions to biotechnology, particularly in glycine transporter research, highlight his role as an innovator in the field. His patents and collaborations reflect a commitment to advancing medical science and improving treatment options for neurological disorders.